Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III pembrolizumab perioperative study in resectable locoregionally advanced head and neck squamous cell carcinoma
2017-001139-38Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Nov 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Pembrolizumab perioperative arm with Standard of care control arm (2 arms). Primary endpoint: Major pathological response. Started Nov 2017; status: active.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2017-001139-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001139-38.